Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D06LYG
|
|||
| Former ID |
DAP000511
|
|||
| Drug Name |
Prilocaine
|
|||
| Synonyms |
Citanest; Prilocaina; Prilocainum; Propitocaine; Prilocaine [USAN]; Prilocaine base; Astra 1512; Astra 1515; L 67; Citanest (TN); Prilocaina [INN-Spanish]; Prilocainum [INN-Latin]; Propitocaine (JAN); Prilocaine (USP/INN); O-Methyl-2-propylaminopropionanilide; O-Methyl-alpha-propylaminopropionanilide; Alpha-n-Propylamino-2-methylpropionanilide; N-[2-Methylphenyl]-2-[propylamino]propanamide; N-(2-methylphenyl)-N2-propylalaninamide; N-(2-Methylphenyl)-2-(propylamino)propanamide; N-(2-methylphenyl)-N(2)-propylalaninamide; Propanamide, N-(2-methylphenyl)-2-(propylamino)-(9CI); 2-(Propylamino)-o-propionotoluidide; 2-Methyl-.alpha.-propylaminopropionanilide; 2-Methyl-alpha-propylaminopropionanilide
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Pain [ICD-11: MG30-MG3Z] | Approved | [1], [2], [3] | |
| Therapeutic Class |
Anesthetics
|
|||
| Company |
Astrazeneca Lp
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C13H20N2O
|
|||
| Canonical SMILES |
CCCNC(C)C(=O)NC1=CC=CC=C1C
|
|||
| InChI |
1S/C13H20N2O/c1-4-9-14-11(3)13(16)15-12-8-6-5-7-10(12)2/h5-8,11,14H,4,9H2,1-3H3,(H,15,16)
|
|||
| InChIKey |
MVFGUOIZUNYYSO-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 721-50-6
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
9734, 95408, 5227596, 7847619, 7980380, 8153018, 10533889, 11336021, 11361260, 11364543, 11367105, 11369667, 11371923, 11375021, 11377829, 11462232, 11466227, 11467347, 11485134, 11485814, 11489365, 11490867, 11493006, 11495463, 15195949, 29223984, 37645318, 46505066, 47440311, 47515365, 47589045, 47662336, 47662337, 47959796, 48035180, 48185043, 48423995, 49698942, 49856374, 50111213, 50476259, 53790341, 85088898, 85171684, 85788442, 90341069, 92719754, 92729955, 103357947, 104253257
|
|||
| ChEBI ID |
CHEBI:8404
|
|||
| ADReCS Drug ID | BADD_D01836 ; BADD_D01837 | |||
| SuperDrug ATC ID |
N01BB04
|
|||
| SuperDrug CAS ID |
cas=000721506
|
|||
| Interaction between the Drug and Microbe | Top | |||
|---|---|---|---|---|
| The Abundace of Studied Microbe(s) Regulated by Drug | ||||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Coriobacteriales | ||||
|
Studied Microbe: Collinsella aerofaciens
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Collinsella aerofaciens was decreased by Prilocaine hydrochloride (adjusted p-values: 1.09E-04). | |||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Voltage-gated sodium channel alpha Nav1.5 (SCN5A) | Target Info | Blocker | [5] |
| KEGG Pathway | Adrenergic signaling in cardiomyocytes | |||
| Pathwhiz Pathway | Muscle/Heart Contraction | |||
| Reactome | Interaction between L1 and Ankyrins | |||
| WikiPathways | SIDS Susceptibility Pathways | |||
| Cardiac Progenitor Differentiation | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7276). | |||
| REF 2 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 076290. | |||
| REF 3 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||
| REF 4 | Extensive impact of non-antibiotic drugs on human gut bacteria. Nature. 2018 Mar 29;555(7698):623-628. | |||
| REF 5 | Monoamine transporter and sodium channel mechanisms in the rapid pressor response to cocaine. Pharmacol Biochem Behav. 1998 Feb;59(2):305-12. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.